Supplementary Figure 4 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer

PDF - 44K, Distribution of the tumor origin across PDX models: Of the 48 PDX tumors, 8 were derived from primary patient tumors, 36 from metastatic sites, 1 from a site of recurring disease, and 1 of unknown anatomical origin. All of the primary tumors (8/8) were associated with phenotype A where aflibercept is more efficacious than bevacizumab. PDX tumors that originated from metastatic tumors were represented in both phenotypes A (30/39) and B (9/9).